UK Alopecia Therapeutics (Hair Loss) Market Report 2022 to 2030

UK Alopecia (Hair Loss) Therapeutics Market Analysis

$ 3999

The UK Alopecia (Hair Loss) Therapeutics Market was valued at US $213 Mn in 2022, and is predicted to grow at (CAGR) of 5.5% from 2023 to 2030, to US $327 Mn by 2030. The key drivers of this industry include the surge in the prevalence of Alopecia (hair loss), increased disposable income, technological advancements, and others. The industry is primarily dominated by players such as Johnson & Johnson, Eli Lilly, Merck, Cipla, Sun Pharmaceuticals, Allergan, and Pfizer, among others.

ID: IN10GBPH430 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Riddhi Solanki

Buy Now

UK Alopecia Therapeutics Market Analysis: Executive Summary

The UK Alopecia (Hair Loss) Therapeutics Market is at around US $213 Mn in 2022 and is projected to reach US $327 Mn in 2030, exhibiting a CAGR of 5.5% during the forecast period.

Alopecia, characterized by irregular hair loss, affects a considerable number of individuals, presenting as localized or diffuse, temporary or permanent, and impacting people of all ages and genders. The condition, stemming from various causes, including heightened stress levels, diabetes, poor nutrition, and environmental influences, can induce significant distress among patients, influencing their overall quality of life. Common symptoms include hair loss, thinning hair, and bald patches on the scalp. Treatment options vary from applying topical medications like minoxidil or corticosteroids directly to the scalp to utilizing injections and oral medications with more potent immunosuppressive effects. Light therapy and hair transplantation are also viable alternatives. Notably, companies like Eli Lilly, with their JAK inhibitor Baricitinib, and Bayer, with Rogaine (minoxidil), are actively leading advancements in treatments for this condition.

The point prevalence of Alopecia areata is approximately 0.58% in UK where female pattern baldness is more common than male pattern baldness. The increased prevalence of alopecia in the UK is attributed to improved diagnostic capabilities and other risk factors. The market is being driven by factors such as the growing aging population and the subsequent surge in Alopecia, improved healthcare access, and technological advancements contributing to the therapeutics industry. However, challenges such as challenges in affording treatments like gene therapy, and regulatory hurdles are a few factors that limit the market's potential.

Market Dynamics

Market Growth Drivers

Surge in prevalence of Alopecia: It is estimated that every 2 in 1000 individuals suffers from alopecia in the UK. The median age of onset in both genders is between 25-30 years, with a greater impact on females. The incidence rate of Alopecia areata is reported to be around 15/10,000 in the UK, and its point prevalence is 0.58% in adults. Increased awareness and improved diagnostic methods contribute to the identification of a larger number of alopecia cases, particularly underdiagnosed types like alopecia areata. The growing life expectancy and aging population play a part in a heightened prevalence of age-related hair loss, including conditions like androgenetic alopecia and cicatricial alopecia.

Improved access to the healthcare system: The National Health Service (NHS) in the UK offers access to diverse treatments for alopecia, although the availability of newer medications may still face limitations due to cost and reimbursement challenges. Growing public awareness campaigns and the presence of online resources empower individuals to educate themselves about and advocate for their treatment choices. Groups such as Alopecia UK actively engage in improving the rates of diagnosis.

Technological advancements: The progress of minimally invasive procedures like hair transplantation techniques and potential upcoming developments in regenerative medicine, such as hair follicle cloning, and gene therapy, contribute to market diversification. Ongoing research, with an emphasis on understanding the unique needs of the UK population and potential genetic factors, has the potential to lead to personalized treatment approaches.

Market Restraints

Affordability challenges: The expenses associated with JAK inhibitors such as Baricitinib (Olumiant) can be substantial, surpassing the budgets of many individuals. Although the National Health Service (NHS) covers medication costs, patients may encounter delays in accessing treatment due to limited availability or prioritization issues. Private insurance coverage for certain alopecia treatments might be restricted, placing additional expenses on some individuals.

Regulatory challenges: Navigating the complex National Institute for Health and Care Excellence (NICE) approval process can lead to delays in accessing newer alopecia medications. This rigorous process evaluates cost-effectiveness before recommending broader coverage within the NHS. Even within the NHS, restrictions on the number of treatment sessions or specific procedures may impede access for certain patients.

Notable Updates

February 2023, The National Institute for Health and Care Excellence (NICE) rejected the recommendation for the routine commissioning of baricitinib, a Janus Kinase Inhibitor drug (JAK inhibitor), for the treatment of severe alopecia areata in adults within the NHS on the basis of cost-effectiveness.

Healthcare Policies and Regulatory Landscape

The healthcare policy and regulatory structure in the United Kingdom are governed by several significant authorities and agencies. Key entities responsible for healthcare regulations and licensing in the UK include the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Care Quality Commission (CQC). The MHRA is tasked with overseeing the regulation of medicines, medical devices, and related services, while the CQC is responsible for ensuring the quality and safety of care provided by healthcare providers in England.

Obtaining a license for healthcare products in the UK requires adherence to the regulations established by these authorities. Companies seeking registration and marketing authorization for pharmaceuticals and medical devices must obtain approval from the MHRA, involving the submission of technical and scientific data to validate the product's safety, quality, and effectiveness.

The healthcare policy and regulatory framework in the United Kingdom involve numerous authorities and agencies, with the MHRA and CQC holding pivotal roles in overseeing healthcare product regulations. Opportunities for companies in the healthcare industry are varied, encompassing both the public and private healthcare sectors in the country.

Competitive Landscape

Key Players

Eli Lilly
Pfizer
Johnson & Johnson
Merck & Co
Allergan
Sun Pharmaceuticals
GlaxoSmithKline plc
Aurobindo Pharma
iRestore Hair Growth system
Theradome

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Alopecia Therapeutics Market Segmentation

By Disease Type

Alopecia Areata
Cicatricial Alopecia
Traction Alopecia
Alopecia Totalis
Androgenetic Alopecia
Alopecia Universalis
Others

By Treatment type

Pharmaceuticals
Devices
Others

By Gender

Male
Female

By Route of Administration

Topical
Injectable
Oral

By Age Group

Below 18 years
18-34 years
35-49 years
50 years and above

By End User

Hospitals
Physician’s Office
Dermatology clinics
Others

By Sales Channel

Prescriptions
OTC

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.